3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
10
Withdrawn
2
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
10
Esophageal Neoplasms
5
Colorectal Neoplasms
5
Rectal Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Adenocarcinoma Of Esophagus
4
Sarcoma
3
Lung Neoplasms
3
Uterine Cervical Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neoplasms
2
Melanoma
2
Vomiting
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Peritoneal Metastases From Gastric Cancer
1
Peritoneal Metastases From Colorectal Cancer
1
Neurofibrosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Nausea
1
Multiple Myeloma
1
Malignant mesenchymal tumor
1
Interventions
Docetaxel
56
Prednisone
36
enzalutamide
25
Leuprolide
24
Magnetic Resonance Spectroscopy
19
Abiraterone Acetate
19
bicalutamide
17
Radiotherapy
15
Goserelin
15
abiraterone
12
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
11
olaparib
9
Androgen Antagonists
9
gallium 68 PSMA-11
8
cabazitaxel
8
Radiotherapy, Intensity-Modulated
8
Metformin
8
Ketoconazole
8
Gonadotropin-Releasing Hormone
8
Cyclophosphamide
8
apalutamide
7
Doxorubicin
7
luprolide acetate gel depot
6
cabozantinib
6
Radiosurgery
6
Estramustine
6
Dexamethasone
6
Calcitriol
6
Biopsy
6
pembrolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Prostatic Neoplasms
×
Neoadjuvant Therapy
×
Clear all
NCT00651326
2023-08-04
DART
Canadian Cancer Trials Group
Phase 3
Terminated
48 enrolled